Institutional Review Board Services (IRB Services) is pleased to announce that it has been awarded full accreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).
IRB Services is the first fully independent, unaffiliated Canadian-based research ethics committee to earn Accreditation from AAHRPP.
AAHRPP accreditation—which translates into significant benefits for research participants and society as a whole—is available to US and international organizations that conduct biomedical, behavioral or social sciences research involving human participants.
Founded in 1993, IRB Services is an independent organization dedicated to protecting the rights and safety of human subjects. IRB Services operates research ethics committees in Toronto, Ontario; Montreal, Quebec; and Boca Raton, Florida, which review a wide range of bothindustry and publicly funded human subject research across multiple disciplines, including Health Canada, Food and Drug Administration, and US Department of Health and Human Services regulated research.
“Since IRB Services operates in an international environment with geographically-dispersed ethics committees dealing with a complex matrix of regulatory and ethical requirements, AAHRPP’s accreditation process has ensured the company meets or exceeds all those obligations and more,” said Jack Corman, President and CEO of IRB Services.
An independent, non-profit accrediting body, AAHRPP uses a voluntary, peer-driven, educational model to ensure that Human Research Protection Programs (HRPP) meet rigorous standards for quality and protection. To earn accreditation, organizations must provide tangible evidence-through policies, procedures, and practices—of their commitment to scientifically and ethically sound research and to continuousimprovement. As the "gold seal," AAHRPP accreditation offers assurances—to research participants, researchers, sponsors, government regulators, and the general public—that an HRPP is focused first and foremost on excellence.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.